SCHEMBL3128374

SCHEMBL3128374

C=CC(O)C1CNCCO1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 15/20 0.35
SLC6A4 P31645 14/20 0.35
SLC6A3 Q01959 11/20 0.35
HRH1 P35367 2/20 0.33
MLNR O43193 1/20 0.33
ADRB2 P07550 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2C P28335 1/20 0.33
OPRK1 P41145 1/20 0.33
KCNH2 Q12809 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27539610 0.78
SCHEMBL87430 0.77 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HRH1MLNR
SCHEMBL146478 0.77 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HRH1MLNR
SCHEMBL3309545 0.77 SLC6A2 (0.35) SLC6A2SLC6A4SLC6A3HRH1MLNR
SCHEMBL3306685 0.74 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3MLNRADRB2
SCHEMBL49735 0.74
SCHEMBL11027407 0.73 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3HRH1MLNR
Bromide SCHEMBL11805140 0.72 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3HRH1MLNR
Hydrochloric Acid SCHEMBL31200743 0.72 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3HRH1MLNR
Hydrochloric Acid SCHEMBL20424103 0.72 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3HRH1MLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4179423-A TERTIARY AMINE, TRIOL, TRICARBOXYLIC ACID ANHYDRIDE SCHENECTADY CHEMICALS, INC. (US) 1979-12-18 US claimed
US-9914709-B2 Compositions and methods of treating HIV-1 infections using same YALE UNIVERSITY (US) 2018-03-13 US disclosed
US-9631045-B2 Polycarbodiimides having onium salt groups PPG INDUSTRIES OHIO, INC. (US) 2017-04-25 US disclosed
US-8981005-B2 Coating compositions that include onium salt group containing polycarbodiimides PPG INDUSTRIES OHIO, INC. (US) 2015-03-17 US disclosed
US-8952006-B2 Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use XENOPORT, INC. (US) 2015-02-10 US disclosed
US-20140378443-A1 Novel Compositions and Methods of Treating HIV-1 Infections Using Same YALE UNIVERSITY 2014-12-25 US disclosed
EP-2812319-A1 MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE XenoPort, Inc. (US) 2014-12-17 EP disclosed
US-20140051705-A1 Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use XENOPORT, INC. (US) 2014-02-20 US disclosed
WO-2013119791-A1 MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE XENOPORT, INC. (US) 2013-08-15 WO disclosed
US-20130203753-A1 MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE XENOPORT, INC. (US) 2013-08-08 US disclosed
EP-0303555-B1 Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament KOEHLER CHEMIE DR FRANZ (DE) 1994-06-15 EP disclosed
EP-0426826-B1 SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES PHARMACIA AB (SE) 1994-04-27 EP disclosed
US-5212305-A Cyclization and forming a carbon-nitrogen bond KABI PHARMACIA AKTIBOLAG (SE) 1993-05-18 US disclosed
US-5155220-A Simplified production of plaque inhibitor KABI PHARMACIA AKTIEBOLAG (SE) 1992-10-13 US disclosed
EP-0426826-A1 SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES. PHARMACIA AB (SE) 1991-05-15 EP disclosed
WO-1990014342-A1 SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES PHARMACIA AB (SE) 1990-11-29 WO disclosed
EP-0303555-A2 Preparation of a metallic chelate of ethanol aminophosphoric acid and medicament Dr. Franz Köhler Chemie GmbH (DE) 1989-02-15 EP disclosed
US-4582904-A REACTING ORGANIC HYDROXY COMPOUND WITH AMMONIA OR AMINE COMPOUND AIR PRODUCTS AND CHEMICALS, INC. (US) 1986-04-15 US disclosed
US-4560798-A SELF CONDENSATION OF ETHANOLAMINE;HIGH SELECTIVITY AIR PRODUCTS AND CHEMICALS, INC. (US) 1985-12-24 US disclosed
US-4048338-A Aqueous cosmetic composition containing amine oxides COLGATE-PALMOLIVE COMPANY (US) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051705-A1 Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use FH, APC, HTT SLC6A2 4712/4885SLC6A4 3547/4885SLC6A3 3690/4885
US-20130203753-A1 MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE FH, APC, HTT SLC6A2 4712/4885SLC6A4 3547/4885SLC6A3 3690/4885
US-20140378443-A1 Novel Compositions and Methods of Treating HIV-1 Infections Using Same CCR5, CCL5, CX3CR1 SLC6A2 4284/4885SLC6A4 4641/4885SLC6A3 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.